

**Disclosures and Conflict of Interest (COI) Mitigation
Faculty, Staff, and Planners' Disclosures**

The following individuals have no relevant financial relationships with ineligible companies to disclose:

Ranjit Banwait MD; Elizabeth Garcia, MPA, BSN, RN, NEA-BC, CPXP; Venus Ginés, M.A. P/CHWI; Lindsay Greenleaf; Chinnadurai Mani, PhD; Michelle Min, DO; Mohammad Jad Moussa, MD, MSc; Ray Page, DO, PhD FACOI, FASCO; Sucharu “Chris” Prakash, MD; Wade Swenson, MD, PhD, MBA, FACP; Shawn Tuma, JD; Lucas Wong, MD, FACP; and the staffs of TxSCO and Physicians’ Education Resource®, LLC.

Faculty	Grant/Research Support	Consultant	Speakers’ Bureau	Shareholder	Other
Ajit Bisen, MD, MBA					Relationships have ended for the following: Advisory Board and Honoraria recipient for Gilead, Biotheranostics Inc. & Novartis. Curio Science Academic Workshop honoraria recipient.
Sanjay Juneja, MD		Daiichi Sakyo, Guardant360	Tempus, Signatera, Merck, AstraZeneca, Daiichi Sankyo, Guardant360, Xeures, Gilead, Anixa Biosciences, Travera, Bristol Myers Squibb		
Kyle Mauro		PhRMA, Alexion Pharmaceuticals, Amgen, Inc., AstraZeneca Pharmaceuticals, LP, Bayer US, LLC, Eli Lilly & Company, Novartis Services, Inc			
Debra Patt, MD, PhD,		Pfizer, Daiichi Sankyo, Inc.			

MBA		(these relationships have ended)			
Benjamin Schrank, MD, PhD					SITC Merck Cancer Immunotherapy Clinical Fellowship
Travis Sims, MD, MPH	Bristol Myers Squibb, Gilead Sciences	Astrazeneca			
Vivek Subbiah, MD	Abbvie, Astex Pharmaceuticals, AstraZeneca, Bayer, Clinical Care Communications, Endeavor BioMedicine, Genmab, Hyku Biosciences, Incyte, Lilly, Loxo Oncology, Novartis, Obsidian Therapeutics, PERS, Pfizer, Pheon Therapeutics, Regeneron, Relay Therapeutics, Roche	Helsinn Healthcare, Jazz Pharmaceuticals, Incyte, Loxo Oncology, Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi Sankyo, R-Pharm US, Illumina, Bayer, Medscape, Onclive			ASCO, ESMO, Helsinn Healthcare, Incyte, Novartis, PharmaMar (Travel Expenses)
Robin Zon, MD				Moderna, Oncolytics Biotech, TG Therapeutics, Select Sector SPDR Health Care, AstraZeneca, Crispr, McKesson, Berkshire Hathaway	

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician, nurse, or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC or the Texas Society of Clinical Oncology (TxSCO).

